Cognitive Test and Assessment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The global cognitive test and assessment market size stood at USD 8.35 billion in 2026, up from USD 7.52 billion in 2025, and is projected to reach USD 13.41 billion by 2031, with a 9.94% CAGR. This report is segmented by Delivery Modality (Paper-Based, Digital, and Remote/Online), End User (Healthcare, Academic, Corporate, Research, Government, and Individual), Application (Diagnosis, Education, Corporate, Trials, Sports, and Wellness), Assessment Type (Neuropsychological, Intelligence, Attention, Language, Aptitude, and Others), and Geography. Value (USD).

Global Cognitive Test and Assessment Market Trends and Insights

Rising Dementia and Neurodegenerative Disease Burden

The cognitive test and assessment market is benefiting from a large, still-rising disease burden. Global dementia prevalence already stands at 55 million people, and the annual incidence remains close to 10 million new cases, which sustains recurring testing demand across diagnosis, staging, and follow-up care. A 2025 peer-reviewed burden study also pointed to a much larger long-term patient base, with global dementia cases projected to reach 153 million by 2050 as populations age further. This matters for the cognitive test and assessment market because each patient typically requires repeated evaluations at multiple treatment points rather than a single one-time test. Earlier biological confirmation is reinforcing that pattern, as the FDA clearance of Fujirebio’s Lumipulse blood test in May 2025 is bringing more patients into structured cognitive evaluation at earlier stages of disease progression.

Growth of Decentralized CNS Clinical Trials

The cognitive test and assessment market is also supported by a clear shift in central nervous system trials toward remote, digital-first study designs. Sponsors are increasingly using digital cognitive endpoints because they reduce site burden, improve recruitment flexibility, and generate higher-frequency data over long study periods. Cogstate reported 133 active clinical trials in its portfolio as of December 31, 2025, which was a 34% year-on-year increase and a direct sign of growing sponsor demand for digital assessment infrastructure. The same disclosure showed 42 new trial starts in the first half of fiscal 2026, versus 25 in the prior comparable period, indicating broader adoption beyond a narrow group of legacy Alzheimer’s studies. Diversification into mood, sleep, and other neurological programs makes trial-related demand in the cognitive test and assessment market more durable by reducing dependence on any single therapeutic area or trial outcome.

Limited Reimbursement Beyond Established Care Pathways

The cognitive test and assessment market still faces uneven reimbursement outside a limited number of established care settings. In the United States, CMS supports cognitive assessment and care planning through CPT code 99483. Still, that framework applies to a defined episode of care rather than the shorter, more frequent digital interactions many remote platforms depend on. That leaves many vendors balancing two distinct demand pools: one tied to reimbursement and another to self-pay, employer funding, or institutional budgets. The gap matters because adoption decisions in the cognitive test and assessment market often depend less on clinical value and more on whether a payer pathway already exists. It also makes international expansion harder, since reimbursement conditions vary widely across countries and often lag behind new digital assessment formats.

Other drivers and restraints analyzed in the detailed report include:

• Telehealth and Mobile Cognitive Testing Adoption
• Alzheimer's Therapy Pathways Increase Repeat Staging Needs
• AI Bias and Weak Cross-Demographic Validation

Segment Analysis

Digital & computer-based assessment held 48.5% of the cognitive test and assessment market share in 2025, making it the largest delivery modality during the period under review. That position reflects a longer transition in the cognitive test and assessment market from paper administration toward validated digital workflows across clinical care, research studies, and publisher-led testing platforms. Pearson’s launch of the all-digital D-KEFS Advanced in September 2025 showed how leading suppliers are no longer just digitizing paper forms, but are redesigning batteries for native tablet use and richer response capture. Digital testing supports faster scoring, more consistent administration, and better data capture, which is especially valuable in high-throughput care settings and multi-site trials. It also gives vendors in the cognitive test and assessment market more flexibility to link results with longitudinal records, remote workflows, and biomarker-led monitoring models.

Paper-based assessment still retains meaningful volume because many clinicians remain anchored to long-standing norms, familiar interpretive frameworks, and psychometric histories that were built around legacy instruments. In parts of the cognitive assessment industry, that installed base still slows migration because providers want confidence that digital formats preserve equivalence across age groups, languages, and device conditions. Remote/Online Assessment is the fastest-growing modality and is forecast to expand at a 10.4% CAGR through 2031, indicating that demand is moving beyond clinic-bound delivery models. Cambridge Cognition’s 2026 Oura-linked brain health study also illustrates where the cognitive test and assessment market is headed, with validated tasks increasingly paired with continuous sleep and physiological data inside connected digital ecosystems. As remote formats mature, the value proposition shifts from simple convenience to sustained longitudinal monitoring, which is a more defensible position for vendors than one-time screening alone.

Healthcare providers held 32.5% of the market in 2025, making them the largest end-user group in the cognitive test and assessment market. Hospitals, clinics, neurology practices, and rehabilitation settings remain central because formal diagnosis, treatment staging, and reimbursed cognitive care planning still occur mainly within provider-led channels. Academic and educational institutions continue to support a steady volume through standardized testing batteries. At the same time, research organizations remain an important customer base for validated tools used in central nervous system studies. Government and defense agencies also maintain demand for specialized readiness and performance tools in operational settings. Corporate buyers are becoming more relevant as well, especially where employers want scalable benchmarking for roles that depend on attention, adaptability, and information processing.

Individual consumers are the fastest-growing end-user group and are forecast to grow at a 11.8% CAGR through 2031, marking a meaningful shift in how the cognitive test and assessment market is accessed. The move is being supported by direct-to-consumer platforms, app-based delivery, and growing public interest in longitudinal brain health tracking rather than only symptom-driven evaluation. Cambridge Cognition’s partnership with Ivory in India is a strong example, since it targets both professional healthcare and consumer health channels and supports multiple Indian languages to broaden reach. The same company disclosure highlighted a major diagnostic gap among older adults in India, underscoring how consumer-led models in the cognitive test and assessment market can extend reach to underdiagnosed populations before a formal clinical visit. This does not replace the clinical channel, but it expands the funnel's front end and brings more people into monitoring earlier in the disease or wellness cycle.

Complete Report Scope:

• By Delivery Modality
  • Paper-Based Assessment
  • Digital & Computer-Based Assessment
  • Remote/Online Assessment
• By End User
  • Healthcare Providers (Hospitals, Clinics & Rehabilitation Centers)
  • Academic & Educational Institutions
  • Corporate Enterprises
  • Research Organizations
  • Government & Defense Agencies
  • Individual Consumers
• By Application
  • Clinical Diagnosis & Monitoring
  • Education & Learning Assessment
  • Corporate & Workforce Assessment
  • Research & Clinical Trials
  • Sports & Performance Management
  • Consumer Brain Health & Wellness
• By Assessment Type
  • Neuropsychological Assessments
  • Intelligence, Memory & Cognitive Ability Tests
  • Attention & Executive Function Assessments
  • Language, Behavioral & Emotional Assessments
  • Aptitude & Skills Assessments
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Peru
    • Chile
    • Argentina
    • Rest of South America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • BENELUX (Belgium, Netherlands, and Luxembourg)
    • NORDICS (Denmark, Finland, Iceland, Norway, and Sweden)
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
    • South East Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines)
    • Rest of Asia-Pacific
  • Middle East And Africa
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of Middle East And Africa

Geography Analysis

North America held 38.3% of the cognitive test and assessment market share in 2025, which made it the largest regional market. The region benefits from mature clinical infrastructure, dense biopharma trial activity, broad familiarity with digital tools, and established Medicare support for cognitive assessment and care planning under CPT code 99483. The cognitive test and assessment market in North America is also being strengthened by U.S. regulatory clarity around digital health technologies in drug development, which helps vendors and sponsors adopt validated cognitive endpoints with less uncertainty. The FDA clearance of the first blood-based Alzheimer’s diagnostic aid in May 2025 is another structural tailwind, because earlier biological confirmation increases the number of patients entering longitudinal assessment pathways. Even with a lower regional growth rate than Asia-Pacific, the North American cognitive test and assessment market remains strategically important because many new product models still need U.S. validation, reimbursement logic, or sponsor traction before scaling elsewhere.

Asia-Pacific is the fastest-growing region and is forecast to expand at a 11.9% CAGR through 2031, positioning it at the center of future demand growth in the cognitive test and assessment market. Japan is a key example, with the National Center for Geriatrics and Gerontology launching the community J-MINT Brain Health Program trial across 19 municipalities beginning in April 2026, pointing to government-backed deployment of structured cognitive prevention activities at scale. India also represents a major growth opportunity, and Cambridge Cognition’s February 2026 partnership with Ivory shows how multilingual digital assessment can be positioned across both professional healthcare and consumer channels in a large underdiagnosed population. The Philippines adds another layer to the regional picture, as DOST-PCHRD funded the NEUROMAP PH project at PHP 60 million, or USD 1.0 million, to strengthen localized early detection and neuroimaging capability.

Europe is forecast to grow at a 6.0% CAGR through 2031, below the global average but supported by stable institutional demand and established clinical infrastructure. The UK government’s December 2025 contract for Pearson Education Limited to provide online educational psychology assessment software and 180 licenses confirms that public-sector procurement remains an active channel for the cognitive test and assessment market in Europe. Cambridge Cognition’s April 2026 result statement also showed recovery and expansion across clinical studies, academic research, professional healthcare, and consumer health and wellness, with 2026 expected revenue of USD 12.4 million (GBP 9.5 million), which indicates that specialist vendors are finding growth in underpenetrated segments. South America, the Middle East, and Africa remain smaller markets for cognitive assessment. Still, digital delivery gives both regions a practical route to scale where specialist infrastructure is less dense. In those markets, mobile and remote assessment models are likely to matter more than traditional, site-heavy formats because they reduce access barriers and better fit uneven provider distribution.

List of Companies Covered in this Report:

• Pearson PLC
• Cambridge Cognition Ltd
• Cogstate Ltd
• Signant Health
• CogniFit Inc
• BrainCheck Inc
• Posit Science Corp (BrainHQ)
• CNS Vital Signs, LLC
• ImPACT Applications Inc
• Linus Health Inc
• Cognivue Inc
• MoCA Test Inc
• Quest Diagnostics Incorporated
• PAR Inc
• Multi-Health Systems (MHS)
• Cognetivity Neurosciences Ltd
• AnthroTronix Inc
• Lumos Labs Inc (Lumosity)
• VeraSci LLC
• Winterlight Labs

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support